Cybin Inc. filings document Helus Pharma's status as a foreign issuer reporting current events through Form 6-K materials and related exhibits. The filings include company news releases covering the HLP003 and HLP004 clinical programs, regulatory designations, clinical research collaborations, scientific advisory matters, and management changes.
The company's regulatory record also covers capital-structure disclosure, shareholder voting matters, governance matters, clinical or regulatory disclosures, operating and financial results, and risk-oriented cautionary statements associated with its clinical-stage pharmaceutical business.
Cybin Inc. (operating commercially as Helus Pharma) reports that Helus Pharma presented four scientific posters on its lead candidate HLP003 for major depressive disorder at Psych Congress 2026. The presentations covered detailed efficacy analyses, psychedelic-experience assessment, expanded safety data from a completed Phase 1/2a study, and a trial-in-progress overview of the ongoing Phase 3 program.
HLP003 is described as an investigational oral deuterated psilocin analog being developed as an adjunctive treatment for major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Cybin also highlights HLP004, another proprietary NSA in Phase 2 development for generalized anxiety disorder, and notes an extensive broader research portfolio of investigational serotonergic agonists.
CYBIN INC. (HELP) reported the initial equity holdings of its Chief Executive Officer, Michael Halstead, in a Form 3 statement of beneficial ownership. As of September 17, 2026, he holds directly 68,568 common shares, 283,334 performance share units and 1,075,000 restricted share units, each representing a contingent right to receive one common share.
The performance share units vest in two tranches upon CYBN common stock achieving specified share-price targets. The restricted share units vest in three equal annual installments, beginning August 3, 2027.
CYBIN INC. (HELP) officer Paul Glavine, Chief Growth Officer, purchased 100,000 Common Shares on September 8, 2026 at $12.4719 per share in an open-market or private transaction. Following this purchase, he holds 4,271,252 Common Shares directly, plus 230,941 Common Shares indirectly held by the PLG Family Trust. The report is filed voluntarily and states he is not subject to Section 16 reporting requirements.
CYBIN INC. (HELP) reported that Chief Growth Officer Paul Glavine voluntarily filed an ownership report showing he purchased 100,000 Common Shares on September 8, 2026 in an open-market or private transaction at $12.4719 per share. After this purchase, he holds 4,271,252 Common Shares directly and 230,941 Common Shares indirectly through the PLG Family Trust. The filing notes he is not otherwise subject to Section 16 reporting requirements and that no Rule 10b5-1 trading plan is reported.
CYBIN INC. (HELP) reported that Executive Chair Eric H. L. So voluntarily filed a Form 4 disclosing an open-market or private purchase of 100,000 Common Shares on September 8, 2026 at $12.3867 per share. Following this purchase, he holds 4,465,014 Common Shares directly and 53,616 Common Shares indirectly through his spouse. No Rule 10b5-1 plan is reported.
Cybin Inc. (Helus Pharma) reported that its commercial operating name, Helus Pharma, will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York City. Chief Executive Officer Michael Halstead is scheduled for a fireside chat on September 16, 2026 at 8:30 a.m. EDT, with a live webcast and replay available through the company’s investor relations website.
The company describes itself as a clinical-stage pharmaceutical business focused on proprietary novel serotonergic agonists (NSAs) aimed at improving treatments for depression, anxiety and other mental health conditions. Its lead candidate HLP003 is in Phase 3 development for adjunctive treatment of major depressive disorder and has received FDA Breakthrough Therapy Designation, while HLP004 is in Phase 2 development for generalized anxiety disorder.
CYBIN INC. (HELP) Executive Chair Eric H. L. So voluntarily reported buying 100,000 Common Shares on September 4, 2026 in an open-market or private purchase at 12.089 per share. Following this purchase, he holds 4,365,014 Common Shares directly and an additional 53,616 shares indirectly, held by his spouse. No Rule 10b5-1 trading plan is reported.
CYBIN INC. (symbol HELP) reports that Chief Growth Officer Paul Glavine purchased 100,000 Common Shares on September 3, 2026 in an open-market or private transaction at an average price of $11.7828 per share. After this trade, he holds 4,171,252 Common Shares directly and 230,941 Common Shares indirectly through the PLG Family Trust. This Form 4 was filed voluntarily, and no Rule 10b5-1 trading plan is reported.
Cybin Inc. (HELP) received a Schedule 13D reporting that co-founder and executive chair Eric So and his spouse Tina So together beneficially own 4,423,894 common shares, representing 5.8% of the company’s common shares.
Eric So holds sole voting and dispositive power over 4,370,278 common shares, including 105,264 shares underlying warrants, and shares voting and dispositive power over 53,616 common shares held by his spouse. On September 1, 2026, he purchased 95,000 common shares at $11.805 per share for a total of $1,121,475, and was awarded 1,046,899 restricted stock units. The holdings were acquired using personal funds and company employee incentive awards, and are described as for investment and incentive purposes.
CYBIN INC. (HELP) reports that Executive Chair Eric H. L. So voluntarily filed a Form 4 disclosing an open-market purchase of 95,000 Common Shares on September 1, 2026 at $11.805 per share. Following this transaction, he holds 4,265,014 Common Shares directly and 53,616 Common Shares indirectly through his spouse. No Rule 10b5-1 trading plan is reported, and the filing notes he is not otherwise subject to Section 16 reporting requirements.